Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? The Oncologist 2015, 20: 1069-1076. PMID: 26194858, PMCID: PMC4571815, DOI: 10.1634/theoncologist.2015-0067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMyelodysplastic syndromeRisk stratificationMDS patientsMolecular testingClinical risk stratification toolHeterogeneous hematopoietic neoplasmsPathophysiology of MDSAccurate risk stratificationIndependent prognostic impactRisk stratification toolImportant clinical endpointsDaily clinical practiceDisease phenotypeCurrent prognostic toolsPrediction of responseMDS therapyPracticing OncologistOverall survivalLaboratory parametersPrognostic impactClinical outcomesStratification toolClinical benefitSpecific therapyClinical endpoints